Novartis prices $5.25B bond sale to refinance Avidity bridge loan
What's the deal? Novartis priced a four-tranche, $5.25 billion senior note offering on November 9, 2026, through its US financing arm, Novartis Capital Corporation. Novartis AG fully and unconditionally guarantees all four tranches, which settle on November 12, 2026.
The tranches. The deal splits into notes maturing in 2029 ($500 million, 4.900%), 2032 ($1.5 billion, 5.200%), 2034 ($1.75 billion, 5.300%), and 2037 (5.500%). Each tranche is expected to carry an Aa3 rating from Moody's and AA- from S&P Global RatingsDealroom has a profile for this one. Try Dealroom →.
Why now? Proceeds will repay the $11 billion bridge loan that financed the roughly $12 billion acquisition of Avidity Biosciences, completed in February 2026. The bond sale swaps short-term borrowing for staggered maturities stretching to 2037.
The debt picture. Net debt reached $37.4 billion at the end of September, up from $21.9 billion at year-end 2025, driven mainly by M&A, dividends, and other outflows. This offering follows an earlier $11 billion bond issuance tied to the same bridge loan.
By the numbers. Novartis reported 2025 net sales of $54.5 billion and net income of $14.0 billion, operating across roughly 120 countries. Barclays, BofA SecuritiesDealroom has a profile for this one. Try Dealroom →, Goldman SachsDealroom has a profile for this one. Try Dealroom →, and Société Générale are among the joint book-running managers.
The signal: At $5.25 billion, this ranks among the largest post-IPO debt raises in Switzerland's health sector, above the 98th percentile of comparable deals. It shows how big pharma is terming out acquisition debt into the bond market as dealmaking reshapes balance sheets.
Read more: kalkinemedia.com
Image credit: ::carlos:capote::
